<p>雅培公司的股价在报告 2024 年第二季度业绩后下跌，销售额达到 103.77 亿美元，每股收益为 1.14 美元，超出预期。尽管 COVID-19 测试销售下降，但其他领域表现强劲，特别是在糖尿病护理、心脏电生理学和结构性心脏方面有增长。营养品销售增长 3.5%，达到 21.5 亿美元。然而，由于 COVID-19 测试收入下降，诊断销售下降了 5.3%。公司获得了各种医疗设备的 FDA 批准和 CE 标志，并获得了两款连续葡萄糖监测系统的认可。雅培公司（ABT）报告了 2024 年第二季度的财务业绩，展示了 4.0% 的销售增长和基础业务有机销售增长 9.3% [1]。这一增长主要得益于医疗设备部门的两位数增长。</p>
<p>尽管 COVID-19 测试销售下降，雅培在其他领域表现强劲。糖尿病护理部门的销售增长了 3.5%，达到 215 亿美元 [1]。心脏电生理学和结构性心脏部门也表现出增长，雅培宣布获得了各种医疗设备的 FDA 批准和 CE 标志 [1]。</p>
<p>然而，由于 COVID-19 测试收入下降，诊断部门经历了 5.3% 的下滑 [1]。这一下滑被雅培在医疗设备部门持续取得的成功和新产品的批准所抵消。</p>
<p>今年 4 月，雅培获得了 Esprit™ 膝下（BTK）系统的 FDA 批准，这是一项对患有周围动脉疾病的人们具有突破性意义的创新 [1]。6 月，雅培获得了两款新的非处方连续葡萄糖监测系统 Lingo™和 Libre Rio™的 FDA 许可，并获得了 AVEIR®双腔（DR）无导联起搏器系统的 CE 标志 [1]。</p>
<p>雅培的研发管线也为公司的增长做出了贡献，在 2024 年上半年宣布了 10 个新的增长机会 [1]。这些机会包括新产品批准和新的治疗适应症，进一步巩固了雅培在医疗保健行业的领先地位。</p>
<p>参考资料：</p>
<p>[1] 雅培报告 2024 年第二季度业绩并提高全年指引。 (2024, 7 月 18 日). 检索自 https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png"/></p>

雅培

<p>尽管雅培（Abbott Laboratories）第二季度业绩稳健，销售额超出预期，但股价下跌。糖尿病护理、心脏电生理学和结构性心脏领域实现增长，而诊断销售下降，原因是 COVID-19 测试收入减少。雅培获得了 FDA 批准和 CE 标志，用于各种医疗设备，并在医疗器械业绩表现强劲。公司的研发管线通过新产品批准和治疗适应症贡献了增长</p>

<p>Abbott Laboratories' shares dropped after reporting Q2 2024 results, with sales at $10.377 billion and EPS at $1.14, exceeding expectations. Despite a decline in COVID-19 testing sales, other sectors showed growth, particularly in diabetes care, electrophysiology, and structural heart. Nutrition sales increased by 3.5% to $2.15 billion. However, diagnostics sales fell 5.3% due to the drop in COVID-19 testing revenue. The company received FDA approvals and CE Marks for various medical devices and cleared two continuous glucose monitoring systems.Abbott Laboratories (ABT) reported its second-quarter 2024 financial results, showcasing a sales growth of 4.0% and an organic sales growth for the underlying base business of 9.3% [1]. This growth was fueled primarily by double-digit growth in the Medical Devices segment.</p>
<div class="lb-trans"><p>雅培公司的股价在报告 2024 年第二季度业绩后下跌，销售额达到 103.77 亿美元，每股收益为 1.14 美元，超出预期。尽管 COVID-19 测试销售下降，但其他领域表现强劲，特别是在糖尿病护理、心脏电生理学和结构性心脏方面有增长。营养品销售增长 3.5%，达到 21.5 亿美元。然而，由于 COVID-19 测试收入下降，诊断销售下降了 5.3%。公司获得了各种医疗设备的 FDA 批准和 CE 标志，并获得了两款连续葡萄糖监测系统的认可。雅培公司（ABT）报告了 2024 年第二季度的财务业绩，展示了 4.0% 的销售增长和基础业务有机销售增长 9.3% [1]。这一增长主要得益于医疗设备部门的两位数增长。</p>
</div><p>Despite a decline in COVID-19 testing sales, Abbott's performance was buoyed by strong growth in other sectors. The Diabetes Care division experienced a 3.5% increase in sales to $2.15 billion [1]. The Electrophysiology and Structural Heart segments also showed growth, with Abbott announcing FDA approvals and CE Marks for various medical devices [1].</p>
<div class="lb-trans"><p>尽管 COVID-19 测试销售下降，雅培在其他领域表现强劲。糖尿病护理部门的销售增长了 3.5%，达到 215 亿美元 [1]。心脏电生理学和结构性心脏部门也表现出增长，雅培宣布获得了各种医疗设备的 FDA 批准和 CE 标志 [1]。</p>
</div><p>However, the Diagnostics segment experienced a 5.3% decline due to the drop in COVID-19 testing revenue [1]. This decline was offset by Abbott's continued success in the Medical Devices segment and the approval of new products.</p>
<div class="lb-trans"><p>然而，由于 COVID-19 测试收入下降，诊断部门经历了 5.3% 的下滑 [1]。这一下滑被雅培在医疗设备部门持续取得的成功和新产品的批准所抵消。</p>
</div><p>In April, Abbott secured FDA approval for the Esprit™ below-the-knee (BTK) system, a groundbreaking innovation for people with peripheral artery disease [1]. In June, Abbott received FDA clearance for two new over-the-counter continuous glucose monitoring systems, Lingo™ and Libre Rio™, and obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system [1].</p>
<div class="lb-trans"><p>今年 4 月，雅培获得了 Esprit™ 膝下（BTK）系统的 FDA 批准，这是一项对患有周围动脉疾病的人们具有突破性意义的创新 [1]。6 月，雅培获得了两款新的非处方连续葡萄糖监测系统 Lingo™和 Libre Rio™的 FDA 许可，并获得了 AVEIR®双腔（DR）无导联起搏器系统的 CE 标志 [1]。</p>
</div><p>Abbott's R&amp;D pipeline has also contributed to the company's growth, with 10 new growth opportunities announced during the first half of 2024 [1]. These opportunities include new product approvals and new treatment indications, further solidifying Abbott's position as a leader in the healthcare industry.</p>
<div class="lb-trans"><p>雅培的研发管线也为公司的增长做出了贡献，在 2024 年上半年宣布了 10 个新的增长机会 [1]。这些机会包括新产品批准和新的治疗适应症，进一步巩固了雅培在医疗保健行业的领先地位。</p>
</div><p>References:</p>
<p>[1] Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance. (2024, July 18). Retrieved from https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
<div class="lb-trans"><p>参考资料：</p>
<p>[1] 雅培报告 2024 年第二季度业绩并提高全年指引。 (2024, 7 月 18 日). 检索自 https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png"/></p>

尽管诊断收入下降，雅培的股票在第二季度稳健的业绩公布后下跌